sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease

The late-onset form of Tay-Sachs disease displays when the activity levels of human β-hexosaminidase A (HexA) fall below 10% of normal, due to mutations that destabilise the native folded form of the enzyme and impair its trafficking to the lysosome. Competitive inhibitors of HexA can rescue disease...

Descripción completa

Detalles Bibliográficos
Autores: González Cuesta, Manuel, Herrera González, Irene, García Moreno, M. Isabel, Ashmus, Roger A., Vocadlo, David J., García Fernández, José Manuel, Nanba, Eiji, Higaki, Katsumi, Ortiz Mellet, Carmen
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/138556
Acceso en línea:https://hdl.handle.net/11441/138556
https://doi.org/10.1080/14756366.2022.2073444
Access Level:acceso abierto
Palabra clave:Iminosugar
Pharmacological chaperone
Thiourea
Thiazolidine
Tay-Sachs
id ES_fed69ec5f658496dcf778ffefeb662a8
oai_identifier_str oai:idus.us.es:11441/138556
network_acronym_str ES
network_name_str España
repository_id_str
spelling sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs diseaseGonzález Cuesta, ManuelHerrera González, IreneGarcía Moreno, M. IsabelAshmus, Roger A.Vocadlo, David J.García Fernández, José ManuelNanba, EijiHigaki, KatsumiOrtiz Mellet, CarmenIminosugarPharmacological chaperoneThioureaThiazolidineTay-SachsThe late-onset form of Tay-Sachs disease displays when the activity levels of human β-hexosaminidase A (HexA) fall below 10% of normal, due to mutations that destabilise the native folded form of the enzyme and impair its trafficking to the lysosome. Competitive inhibitors of HexA can rescue disease-causative mutant HexA, bearing potential as pharmacological chaperones, but often also inhibit the enzyme O-glucosaminidase (GlcNAcase; OGA), a serious drawback for translation into the clinic. We have designed sp2-iminosugar glycomimetics related to GalNAc that feature a neutral piperidine-derived thiourea or a basic piperidine-thiazolidine bicyclic core and behave as selective nanomolar competitive inhibitors of human Hex A at pH 7 with a ten-fold lower inhibitory potency at pH 5, a good indication for pharmacological chaperoning. They increased the levels of lysosomal HexA activity in Tay-Sachs patient fibroblasts having the G269S mutation, the highest prevalent in late-onset Tay-Sachs disease.Ministerio de Ciencia e Innovación 10.13039/50110001103Fondo Europeo de Desarrollo Regional PID2019-105858RB-I00, RTI2018-097609-B-C21Junta de Andalucía P20_00166Canadian Institutes of Health Research MOP-123341Natural Sciences and Engineering Research Council of Canada RGPIN-06466Japan Society for the Promotion of Science 17K10051Universidad de Sevilla BES-2017–079676, FPU17/03147Taylor & FrancisQuímica OrgánicaMinisterio de Ciencia e Innovación (MICIN). EspañaFondo Europeo de Desarrollo Regional (FEDER)Junta de AndalucíaCanadian Institutes of Health ResearchNatural Sciences and Engineering Research Council of Canada (NSERC)Japan Society for the Promotion of ScienceUniversidad de Sevilla2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/138556https://doi.org/10.1080/14756366.2022.2073444reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésJournal of Enzyme Inhibition and Medicinal Chemistry, 37 (1), 1364 - 1374.10.13039/50110001103PID2019-105858RB-I00RTI2018-097609-B-C21P20_00166MOP-123341RGPIN-0646617K10051BES-2017–079676FPU17/03147https://doi.org/10.1080/14756366.2022.2073444info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1385562026-06-17T12:51:07Z
dc.title.none.fl_str_mv sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
title sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
spellingShingle sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
González Cuesta, Manuel
Iminosugar
Pharmacological chaperone
Thiourea
Thiazolidine
Tay-Sachs
title_short sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
title_full sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
title_fullStr sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
title_full_unstemmed sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
title_sort sp2-Iminosugars targeting human lysosomal β-hexosaminidase as pharmacological chaperone candidates for late-onset Tay-Sachs disease
dc.creator.none.fl_str_mv González Cuesta, Manuel
Herrera González, Irene
García Moreno, M. Isabel
Ashmus, Roger A.
Vocadlo, David J.
García Fernández, José Manuel
Nanba, Eiji
Higaki, Katsumi
Ortiz Mellet, Carmen
author González Cuesta, Manuel
author_facet González Cuesta, Manuel
Herrera González, Irene
García Moreno, M. Isabel
Ashmus, Roger A.
Vocadlo, David J.
García Fernández, José Manuel
Nanba, Eiji
Higaki, Katsumi
Ortiz Mellet, Carmen
author_role author
author2 Herrera González, Irene
García Moreno, M. Isabel
Ashmus, Roger A.
Vocadlo, David J.
García Fernández, José Manuel
Nanba, Eiji
Higaki, Katsumi
Ortiz Mellet, Carmen
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Química Orgánica
Ministerio de Ciencia e Innovación (MICIN). España
Fondo Europeo de Desarrollo Regional (FEDER)
Junta de Andalucía
Canadian Institutes of Health Research
Natural Sciences and Engineering Research Council of Canada (NSERC)
Japan Society for the Promotion of Science
Universidad de Sevilla
dc.subject.none.fl_str_mv Iminosugar
Pharmacological chaperone
Thiourea
Thiazolidine
Tay-Sachs
topic Iminosugar
Pharmacological chaperone
Thiourea
Thiazolidine
Tay-Sachs
description The late-onset form of Tay-Sachs disease displays when the activity levels of human β-hexosaminidase A (HexA) fall below 10% of normal, due to mutations that destabilise the native folded form of the enzyme and impair its trafficking to the lysosome. Competitive inhibitors of HexA can rescue disease-causative mutant HexA, bearing potential as pharmacological chaperones, but often also inhibit the enzyme O-glucosaminidase (GlcNAcase; OGA), a serious drawback for translation into the clinic. We have designed sp2-iminosugar glycomimetics related to GalNAc that feature a neutral piperidine-derived thiourea or a basic piperidine-thiazolidine bicyclic core and behave as selective nanomolar competitive inhibitors of human Hex A at pH 7 with a ten-fold lower inhibitory potency at pH 5, a good indication for pharmacological chaperoning. They increased the levels of lysosomal HexA activity in Tay-Sachs patient fibroblasts having the G269S mutation, the highest prevalent in late-onset Tay-Sachs disease.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/138556
https://doi.org/10.1080/14756366.2022.2073444
url https://hdl.handle.net/11441/138556
https://doi.org/10.1080/14756366.2022.2073444
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Journal of Enzyme Inhibition and Medicinal Chemistry, 37 (1), 1364 - 1374.
10.13039/50110001103
PID2019-105858RB-I00
RTI2018-097609-B-C21
P20_00166
MOP-123341
RGPIN-06466
17K10051
BES-2017–079676
FPU17/03147
https://doi.org/10.1080/14756366.2022.2073444
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425720494653440
score 15.301629